Mexiletine effectively prevented refractory Torsades de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome

J Cardiovasc Electrophysiol. 2022 Jul;33(7):1592-1595. doi: 10.1111/jce.15517. Epub 2022 May 8.

Abstract

We report a 28-year-old female patient with congenital type 2 long QT syndrome (LQTS) in which mexiletine shortened corrected QT interval (QTc) and effectively prevented refractory Torsade de Pointes (TdP) and ventricular fibrillation (VF). She developed TdP and VF, and was subsequently diagnosed with congenital type 2 LQTS. She had refractory TdP and VF every day despite medical therapy including β-blocker. They were completely suppressed after the initiation of mexiletine with shorting of QTc interval.

Keywords: long QT syndrome; mexiletine; torsade de pointes; ventricular fibrillation.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Arrhythmias, Cardiac
  • DNA-Binding Proteins
  • Electrocardiography
  • Female
  • Humans
  • Long QT Syndrome* / complications
  • Long QT Syndrome* / diagnosis
  • Long QT Syndrome* / drug therapy
  • Mexiletine / therapeutic use
  • Torsades de Pointes* / diagnosis
  • Torsades de Pointes* / etiology
  • Ventricular Fibrillation / diagnosis
  • Ventricular Fibrillation / etiology
  • Ventricular Fibrillation / prevention & control

Substances

  • DNA-Binding Proteins
  • Mexiletine